Wegovy Side Effects: What's Normal vs Concerning

Most people who start Wegovy (semaglutide) experience some degree of nausea, digestive upset, or appetite change, especially during the first few months of dose increases. These gastrointestinal effects are expected and usually manageable. A smaller number of people develop more serious reactions, such as signs of pancreatitis, gallbladder disease, or severe allergic reactions, that require prompt medical evaluation rather than waiting it out. Knowing the difference can help you respond appropriately instead of either tolerating something dangerous or stopping a medication unnecessarily over a side effect that would have resolved with time or a dosing adjustment.

Wegovy is the brand name for semaglutide 2.4 mg, a GLP-1 receptor agonist approved by the FDA for chronic weight management in adults and certain adolescents with obesity or overweight with a weight-related condition. It works by mimicking a gut hormone that slows stomach emptying, reduces appetite, and affects blood sugar regulation. This mechanism explains why digestive symptoms are the most common complaint, and why the dose is increased gradually over weeks rather than started at the full treatment dose.

It's worth noting that Wegovy is distinct from compounded semaglutide products sometimes marketed online or at non-medical outlets. Compounded versions are not FDA-approved, are not held to the same manufacturing and quality standards, and their side effect data is less well characterized. The information below applies specifically to the FDA-approved product.

Common Wegovy Side Effects You Can Expect

In the clinical trials that supported Wegovy's approval, the most frequently reported side effects were gastrointestinal. These typically appear or intensify after a dose increase and often ease within one to two weeks as the body adjusts.

Nausea is the most common complaint, reported by close to half of trial participants at some point during treatment. It tends to be mild to moderate and is usually most noticeable in the days following a dose step-up.

Other frequently reported effects include:

- Vomiting

- Diarrhea

- Constipation

- Abdominal pain or discomfort

- Bloating, gas, or belching

- Heartburn or acid reflux

- Headache

- Fatigue

- Dizziness

Most of these symptoms are dose-related, meaning they are more likely right after an increase and tend to settle at a stable dose. The Wegovy dosing schedule is designed around this pattern: treatment starts at 0.25 mg weekly and increases every four weeks, through 0.5 mg, 1 mg, and 1.7 mg, up to the maintenance dose of 2.4 mg. This gradual approach is the main built-in strategy for minimizing side effects, which is why skipping steps or self-adjusting the schedule is not recommended without clinical guidance.

Practical Ways to Reduce GI Symptoms

Several simple habits can make the early weeks more comfortable:

- Eat smaller meals and stop when comfortably full rather than full.

- Limit high-fat, fried, or very rich foods, which slow digestion further and can worsen nausea.

- Eat slowly and avoid lying down immediately after meals.

- Stay well hydrated, particularly if diarrhea or vomiting occurs, since dehydration can contribute to more serious complications (discussed below).

- Ask your prescriber about timing the injection relative to meals or your weekly schedule if symptoms cluster around certain days.

If nausea or GI upset is persistent but not severe, many clinicians will keep a patient at a lower dose longer before increasing, rather than stopping the medication altogether.

Serious Wegovy Side Effects That Need Immediate Attention

A smaller set of Wegovy side effects are not just uncomfortable, they signal a potential medical complication. These warrant contacting a clinician promptly, and some warrant emergency care.

Pancreatitis. Severe abdominal pain, often radiating to the back, with or without vomiting, can indicate inflammation of the pancreas. This is uncommon but serious, and Wegovy's prescribing information carries a warning about this risk. Anyone with this symptom pattern should seek medical evaluation the same day.

Gallbladder problems. Rapid weight loss itself increases the risk of gallstones, and semaglutide use has been associated with gallbladder disease including cholecystitis. Warning signs include pain in the upper right abdomen, fever, or yellowing of the skin or eyes (jaundice).

Kidney injury. Significant vomiting or diarrhea can lead to dehydration, which in some cases has triggered acute kidney injury in people taking GLP-1 medications. Reduced urination, unusual fatigue, confusion, or dizziness after a stretch of poor fluid intake should prompt a call to your care team.

Thyroid tumor warning. Wegovy carries a boxed warning, the FDA's most serious warning category, because semaglutide caused thyroid C-cell tumors in rodent studies. Whether this risk applies to humans is unknown, but because of this uncertainty, Wegovy is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. A new lump or swelling in the neck, hoarseness, or difficulty swallowing should be evaluated promptly.

Hypoglycemia. This is more relevant for people also taking insulin or sulfonylureas for type 2 diabetes. Symptoms include shakiness, sweating, confusion, or fainting.

Vision changes. People with type 2 diabetes and existing diabetic retinopathy have shown a possible increased risk of retinopathy complications with semaglutide treatment. New or worsening vision problems should be reported to both the prescribing clinician and an eye care provider.

Allergic reactions. Facial or throat swelling, difficulty breathing, widespread rash, or hives can indicate a hypersensitivity reaction and require emergency care.

Mood and mental health changes. The FDA has required monitoring for suicidal thoughts or behavior with GLP-1 medications as a precaution while this association is studied further; a causal link has not been established, but any new or worsening depression, anxiety, or thoughts of self-harm should be reported immediately and are not something to manage by waiting for a routine follow-up.

Surgery and anesthesia considerations. Because semaglutide slows stomach emptying, there is a recognized risk of aspiration during procedures requiring sedation or general anesthesia. If you have an upcoming surgery or procedure, tell both your surgeon and your Wegovy prescriber so they can coordinate timing around your dose.

Any of the following should prompt a same-day call to your prescriber or a visit to urgent care or the emergency department, depending on severity: persistent vomiting that prevents keeping fluids down, severe or worsening abdominal pain, signs of an allergic reaction, significant vision changes, a racing or irregular heartbeat with dizziness or fainting, or thoughts of self-harm.

When to Adjust Your Dose vs When to Stop Wegovy

The decision between adjusting the dose, pausing treatment, or stopping Wegovy altogether depends on the type and severity of the symptom, not just its presence.

Dose adjustment is usually appropriate when:

- Nausea, mild diarrhea, or constipation appears after a dose increase but is tolerable with dietary changes.

- Symptoms are improving over days to a couple of weeks.

- There is no sign of dehydration, severe pain, or the serious warning signs listed above.

In these situations, a clinician may keep you at your current dose longer before the next scheduled increase, or in some cases temporarily reduce the dose, rather than discontinuing treatment.

Stopping or pausing Wegovy and seeking medical guidance is appropriate when:

- Severe abdominal pain, especially radiating to the back, develops.

- Signs of gallbladder disease, kidney injury, or an allergic reaction appear.

- Vomiting or diarrhea is severe enough to prevent adequate fluid intake.

- New vision changes, a thyroid lump, or mood changes including suicidal thoughts occur.

In these cases, do not wait for a scheduled follow-up appointment. Contact your prescriber promptly, and use emergency services for severe or rapidly worsening symptoms, chest pain, difficulty breathing, or signs of a severe allergic reaction.

It's also worth discussing with your clinician whether you are on the right GLP-1 product for your situation. Wegovy is a GLP-1 receptor agonist only; dual GIP/GLP-1 medications such as tirzepatide work somewhat differently and can have a different tolerability profile for some patients. This is a conversation for your prescriber, not a reason to switch medications on your own.

A brief personal note matters here: side effect patterns, medical history, and other medications all affect how Wegovy should be dosed and monitored for a given individual. The guidance above is general education, not a substitute for a clinician who knows your full history evaluating your specific symptoms.

Getting Individualized Support

If you're currently using Wegovy or considering starting a GLP-1 medication and want your side effects, dosing schedule, or eligibility reviewed by a clinician, Maryland Trim Clinic's GLP-1 weight-management program in Laurel, Maryland includes medical evaluation and follow-up as part of care. You can also review the clinic's broader medical weight loss program or contact the clinic to discuss your specific situation. Starting or continuing a GLP-1 medication should always involve an individualized evaluation rather than general information alone.

The Bottom Line

Nausea, mild GI upset, fatigue, and headache are common with Wegovy, particularly around dose increases, and typically improve with time and simple dietary adjustments. Severe abdominal pain, signs of gallbladder or kidney problems, allergic reactions, vision changes, a thyroid lump, or new mental health symptoms are not something to manage on your own. Tracking which category a symptom falls into, and communicating promptly with your prescriber, is the safest way to stay on treatment when appropriate and to get help quickly when something is genuinely wrong.

———

Frequently Asked Questions

Q: How long do Wegovy side effects typically last?

A: Gastrointestinal side effects like nausea, bloating, or constipation are most common in the days after a dose increase and often ease within one to two weeks as the body adjusts to that dose. If a symptom is not improving after a few weeks at a stable dose, or is getting worse, discuss it with your prescriber rather than assuming it will resolve on its own.

Q: Can I manage nausea without stopping Wegovy?

A: Many people manage nausea by eating smaller, lower-fat meals, eating slowly, stopping before feeling overly full, and staying hydrated. If nausea remains mild to moderate and is not accompanied by severe pain, persistent vomiting, or dehydration, these strategies combined with clinician-guided dose pacing are often enough without discontinuing treatment.

Q: Is hair loss a known Wegovy side effect?

A: Hair thinning has been reported anecdotally with significant or rapid weight loss on GLP-1 medications, including semaglutide, and is more often linked to the physiological effects of substantial weight change than to a direct drug effect. It was not listed as a primary adverse reaction in Wegovy's clinical trials. If you notice hair thinning, mention it to your prescriber so other causes, such as nutritional intake, can be reviewed.

Q: Does Wegovy cause depression or suicidal thoughts?

A: A direct causal link between semaglutide and suicidal thoughts or behavior has not been established, but the FDA has required ongoing monitoring for this possibility as a precaution. Any new or worsening depression, anxiety, or thoughts of self-harm while taking Wegovy should be reported to a clinician immediately rather than waiting for a scheduled visit.

Q: What should I do if I have severe abdominal pain after a Wegovy injection?

A: Severe abdominal pain, especially if it radiates to the back and occurs with or without vomiting, can be a sign of pancreatitis and should be evaluated promptly, the same day if possible. This is different from the mild stomach discomfort or bloating that is common with GLP-1 medications, and it should not be managed by simply waiting it out.